Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.37 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030663 | 0.86 | WDR5 (0.46) | WDR5GAAALDH1A1POLBGSTO1 | |
| SCHEMBL6761723 | 0.84 | WDR5 (0.47) | WDR5MEP1BBDKRB2BDKRB1ALDH1A1 | |
| SCHEMBL6761822 | 0.79 | PTGES2 (0.49) | ALDH1A1KMT2ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6766636 | 0.76 | ALDH1A1 (0.45) | WDR5GAAALDH1A1POLBPKM | |
| SCHEMBL6846253 | 0.76 | GAA (0.52) | GAAALDH1A1POLBGSTO1 | |
| SCHEMBL5119703 | 0.75 | WDR5 (0.47) | WDR5BDKRB2BDKRB1ALDH1A1POLB | |
| SCHEMBL5119706 | 0.75 | WDR5 (0.47) | WDR5BDKRB2BDKRB1ALDH1A1POLB | |
| SCHEMBL6763294 | 0.75 | SMN1; SMN2 (0.44) | WDR5GAAALDH1A1POLBPKM | |
| SCHEMBL4030951 | 0.74 | WDR5 (0.50) | WDR5GAABDKRB2BDKRB1ALDH1A1 | |
| SCHEMBL6851806 | 0.73 | ATM (0.47) | MEP1BGAAALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521744-B1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER LAB SA (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
| EP-1521744-A1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-13 | — | — | EP | disclosed |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
| WO-2003106428-A1 | NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATOIRES FOURNIER SA (FR) | 2003-12-24 | — | — | WO | disclosed |
| EP-1351928-A2 | NOVEL N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER S.A. (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002053516-A2 | N(PHENYLSULPHONYL)GLYCINE DERIVATIVES AND THEIR THERAPEUTIC USE | LABORATOIRES FOURNIER SA (FR) | 2002-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | WDR5 3992/4885MEP1B 723/4885GAA 215/4885 |
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | WDR5 4094/4885MEP1B 1832/4885GAA 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.